Creso shifts gears

"A new phase of execution."

• Mr William Lay, appointed as Group CEO and Managing Director.
  Bruce Linton appointed as Non-Executive Director.
• Mrs Micheline MacKay, Mernova’s Corporate Manager appointed as Executive Director.

Mr Lay and Mr Linton worked closely together during their time at Canopy Growth, assessing, overseeing and executing over C$5Bn in cannabis transactions, including the industry’s largest acquisition to date.

Mr William Lay is an experienced cannabis executive and previously served as Executive Vice President – Strategy, Origination & Operations at Creso Pharma. Mr Lay began his career with leading Canadian full service financial investment
bank, BMO Capital Markets through roles across Canada and London.
Shortly after his time with BMO Capital Markets, Mr Lay joined Canopy Growth Corporation (TSE:WEED, NASDAQ: CGC) as an M&A Associate, before being promoted to Associate Director, M&A, in 2019. In this role, he assessed and effected multiple transactions locally and internationally, while concurrently progressing corporate strategy initiatives across the group. During his time at Canopy Growth, Mr Lay built a strong working relationship with Mr Linton, working on many high-profile initiatives together. Over the last four years, Mr Lay has managed and supported over C$5 billion in cannabis M&A transactions, including leading the largest acquisition in the history of the cannabis sector. In his new role as CEO and Managing Director of Creso Pharma, he will progress the Company’s North American focused growth strategy, as well as Creso Pharma’s proposed NASDAQ dual listing. Mr Lay will also oversee the Company’s global operations, including Creso Pharma’s Swiss division and potential new market entries. Creso Pharma plans to leverage Mr Lay’s extensive expertise to assess strategic, value accretive acquisitions in regions where it has an existing footprint, as well as for expansion purposes, with a particular focus on North America.